Open Access. Powered by Scholars. Published by Universities.®
Pharmacy and Pharmaceutical Sciences Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Synthases (3)
- 5-EPI-Aristolochene (1)
- Antagonist (1)
- Bridged (1)
- CNS pathologies (1)
-
- Camptothecin analogues (1)
- Compounds (1)
- Elicitor-Inducible Transcription (1)
- Formulation (1)
- Genes (1)
- Nicotine (1)
- Opioid (1)
- Pathogen (1)
- Pharmaceutical (1)
- Plants (1)
- Poorly water soluble (1)
- Products (1)
- Regulatory Element (1)
- Synthase (1)
- Tobacco (1)
- Transdermal (1)
- Transform (1)
- Treatment (1)
Articles 1 - 7 of 7
Full-Text Articles in Pharmacy and Pharmaceutical Sciences
Pharmaceutical Formulation For Poorly Water Soluble Camptothecin Analogues, Tiang-Xiang Xiang, Bradley D. Anderson
Pharmaceutical Formulation For Poorly Water Soluble Camptothecin Analogues, Tiang-Xiang Xiang, Bradley D. Anderson
Pharmaceutical Sciences Faculty Patents
The present invention provides a general method to retard the precipitation inception time for poorly water-soluble camptothecin analogues from a supersaturated solution by a chemical conversion approach via pH alteration. This method is successfully utilized to prepare stable parenteral formulations for silatecan 7-t-butyldimethylsilyl-10-hydroxycamptothecin (DB-67), a poorly water-soluble lipophilic camptothecin analogue, in aqueous solutions containing β-cyclodextrin sulfobutyl ether (SBE-CD) or other solubilizing agents. The formulations manufactured by this method are more simple and cost-effective, of higher doses and better quality in terms of manufacture loss and formulation stability, and can be free of organic solvents (e.g., DMSO or N-methyl-2-pyrrolidinone).
Synthases, Joseph Chappell, Kathleen R. Manna, Joseph P. Noel, Courtney M. Starks
Synthases, Joseph Chappell, Kathleen R. Manna, Joseph P. Noel, Courtney M. Starks
Pharmaceutical Sciences Faculty Patents
Novel synthases and the corresponding nucleic acids encoding such synthases are disclosed herein. Such synthases possess an active site pocket that includes key amino acid residues that are modified to generate desired terpenoid reaction intermediates and products. Synthase modifications are designed based on, e.g., the three-dimensional coordinates of tobacco 5-epi-aristolochene synthase, with or without a substrate bound in the active site.
Pathogen- Or Elicitor-Inducible Transcription Regulatory Element From The Tobacco 5-Epi-Aristolochene Synthase Gene And Plants Transformed Therewith, Joseph Chappell, Shaohui Yin, Catherine Cornett
Pathogen- Or Elicitor-Inducible Transcription Regulatory Element From The Tobacco 5-Epi-Aristolochene Synthase Gene And Plants Transformed Therewith, Joseph Chappell, Shaohui Yin, Catherine Cornett
Pharmaceutical Sciences Faculty Patents
A tobacco epi-5-aristolochene synthase transcriptional regulatory element functional in plants, plant tissue and in plant cells for pathogen inducible gene expression and a method for increasing the transcriptional expression of downstream genetic information in plants, plant tissue and plant cells are disclosed.
Synthases, Joe Chappell, Kathleen R. Manna, Joseph P. Noel, Courtney M. Starks
Synthases, Joe Chappell, Kathleen R. Manna, Joseph P. Noel, Courtney M. Starks
Pharmaceutical Sciences Faculty Patents
Novel synthases and the corresponding nucleic acids encoding such synthases are disclosed herein. Such synthases possess an active site pocket that includes key amino acid residues that are modified to generate desired terpenoid reaction intermediates and products. Synthase modifications are designed based on, e.g., the three-dimensional coordinates of tobacco 5-epi-aristolochene synthase, with or without a substrate bound in the active site.
Transdemal Delivery Of Opioid Antagonist Prodrugs, Audra L. Stinchcomb, Peter W. Swaan
Transdemal Delivery Of Opioid Antagonist Prodrugs, Audra L. Stinchcomb, Peter W. Swaan
Pharmaceutical Sciences Faculty Patents
A composition, a method and an apparatus for transdermally delivering an effective amount of opioid antagonists derived from prodrugs for treatment of eating disorders, narcotic dependence and alcoholism. In addition, the present invention relates to a composition, a method and an apparatus for transdermally delivering an effective amount of an opioid and opioid antagonist derived from an opioid agonist and one of an opioid antagonist and a prodrug for treatment of pain.
Synthases, Joe Chappell, Kathleen R. Manna, Joseph P. Noel, Courtney M. Starks
Synthases, Joe Chappell, Kathleen R. Manna, Joseph P. Noel, Courtney M. Starks
Pharmaceutical Sciences Faculty Patents
Novel synthases and the corresponding nucleic acids encoding such synthases are disclosed herein. Such synthases possess an active site pocket that includes key amino acid residues that are modified to generate desired terpenoid reaction intermediates and products. Synthase modifications are designed based on, e.g., the three-dimensional coordinates of tobacco 5-epi-aristolochene synthase, with or without a substrate bound in the active site.
Bridged Nicotine Compounds For Use In The Treatment Of Cns Pathologies, Peter A. Crooks, Linda P. Dwoskin, Rui Xu, Vladimir P. Grinevich
Bridged Nicotine Compounds For Use In The Treatment Of Cns Pathologies, Peter A. Crooks, Linda P. Dwoskin, Rui Xu, Vladimir P. Grinevich
Pharmaceutical Sciences Faculty Patents
Pharmaceutical compounds comprising bridged nicotine analogs of N-octylnicotinium iodide (NONI) having selective antagonist properties at α3β2-containing nicotinic receptor subtypes, and compositions containing these compounds. The compounds and compositions are used to treat central nervous system pathologies.